•  

Posts Tagged: drug discovery

Biotechnology Focus’ December issue covers MaRS Innovation projects and partnerships

MaRS Innovation's (MI) projects and partnerships earned three separate article mentions in the December 2012 issue of Biotechnology Focus, including: MI and UHN's partnership with Stem Cell Therapeutics was covered in the magazine's Dealmakers subsection. Read the write-up on the Biotechnology Focus website. Cellax, a licensable technology that may produce a nanotechonology-based cancer drug, was highlighted in the magazine's Business Corner section (read the write-up). Cellax is a joint project between MI and the Ontario Institute for Cancer Research. MaRS Innovation's ... Read more

Gen Magazine features Dr. Aaron Wheeler’s research in microfluidics

GEN Magazine (Genetic Engineering and Biotechnology News) featured the microfluidics research of Dr. Aaron Wheeler on November 15, 2012. Wheeler, Canada Research Chair of Bioanalytical Chemistry and an associate professor at the University of Toronto, has made an invention disclosure to MaRS Innovation; Kapplex is the start-up company created to commercialize his research. (more…) Read more

Baxter and MaRS Innovation Form Strategic Partnership

Partnership to invest up to $1M in promising Canadian healthcare discoveries TORONTO, Ontario, October 4, 2012—Baxter International Inc. and MaRS Innovation, a Centre of Excellence for Commercialization and Research, have entered into a strategic partnership to commercialize early-stage technologies that present innovative methods in therapeutics and drug discovery technologies. Information about Baxter and MaRS Innovation's partnership is also available in French. The partnership’s shared vision for delivering novel, transformative therapeutic technologies will benefit Canadians and others around the world. Baxter and MaRS Innovation will ... Read more

Business Without Borders features Encycle Therapeutics, Raphael Hofstein

Encycle Therapeutics, a MaRS Innovation spin-off company, was featured by Business Without Borders' High Tech section in a Q&A profile with MI's President and CEO, Raphael Hofstein. Here's an excerpt: Business Without Borders (BWB): What makes Encycle’s technology so promising? Raphael Hofstein (RH): Proteins are made of smaller units called peptides, usually existing as linear chains. If they get into the bloodstream, they get degraded rapidly by enzymes and they find it very difficult to get into cells of the body. What we want ... Read more

Montreal’s La Presse covers life science research funding project among MI, CQDM, OCE and OBI

This week, MaRS Innovation (MI) announced a new partnership agreement with The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute (OBI) and Ontario Centres of Excellence (OCE) to launch the Québec/Ontario CQDM Funding Program. The funding program will support collaborative life science research projects between the two provinces that seek to develop new tools for biopharmaceutical research. (more…) Read more

Encycle Therapeutics Launches Ground-Breaking Chemistry Platform

Platform for cyclizing peptides promises to increase efficiency of early-stage drug discovery BOSTON, June 18, 2012 - Encycle Therapeutics, a MaRS Innovation spin-off company, has created a ground-breaking chemistry platform for cyclizing peptides that promises to increase the efficiency of the early-stage drug discovery process. Peptides have long been sought after as therapeutics due to their high specificity — they can hit specific cellular targets, especially complex protein-protein interaction targets implicated in cancer, cardiovascular disease and metabolic disorders. (more…) Read more

Encycle investigators receive CQDM investment

CQDM invests $1.5 million in two collaborative projects within the Québec/Ontario Life Sciences Corridor Toronto, December 6, 2011 —  The Québec Consortium for Drug Discovery (CQDM) is pleased to announce $1.5 million in funding for two joint Québec/Ontario research projects in biomedical research. The news was released today at the conference, Connecting Life Sciences Across the Ontario-Québec Corridor, which was held in Toronto. (more…) Read more

MaRS Innovation and GlaxoSmithKline Announce Strategic Partnership to Accelerate Translational Research in Health Sciences

TORONTO (May 31, 2011) — MaRS Innovation (MI) and GlaxoSmithKline Inc. (GSK) today announced a new development fund — the GSK-MaRS Innovation Fund — that will support and fast-track the commercialization of some of the country’s most promising translational research coming from 16 leading academic health sciences centres, hospitals and universities derived from MI’s member institutions. “From the discovery of insulin in 1922 to the discovery of stem cells, Ontario has a rich, proud history of world-class medical and scientific breakthroughs,” said ... Read more
Page 2 of 212